{"product_id":"bnr-ansoff-analysis","title":"(BNR) Burning Rock Biotech Limited ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Full Ansoff Matrix for Deeper Strategic Insight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Burning Rock Biotech Limited Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification and is designed for strategy, investment, or research use; the page includes a real preview\/sample of the analysis so you can judge style and substance before buying—purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-hospital adoption of OncoScreen IO and OncoCompass IO\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited can grow share in China’s oncology testing market by moving OncoScreen IO and OncoCompass IO deeper into hospitals, where they can lift repeat test volume without expanding the core market. China had about 4.82 million new cancer cases in 2022, and these assays target high-burden tumors like lung, gastrointestinal, breast, prostate, and colorectal disease.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentral laboratory volume growth for multi-cancer testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited can keep growing Central Laboratory volume by selling more established multi-cancer tests through the same Chinese referral channels. Its tissue and liquid biopsy workflow supports repeat orders and makes it easier for hospitals to choose one provider for more cases. This is a direct share-gain move, not a new-market bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCTDNA and tissue dual-modality selling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s dual-modality setup lets it place ctDNA and tissue tests in the same account, so physicians can match OncoCompass IO, OncoCompass Target, and OncoScreen IO to the clinical need. In FY2025, that kind of cross-sell model supports deeper hospital use and lowers churn versus single-test rivals. It also raises wallet share inside existing lab and hospital accounts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiomarker-led selling in NSCLC, GI, prostate, and HRD testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited can push market penetration by selling OncoCompass Target in NSCLC, ColonCore in GI cancers, and ParpMatch in HRD-linked genes where these tests already fit routine Chinese oncology care. These are high-volume, high-value segments, so tighter hospital promotion and test-pathway capture can lift use of current products faster than new launches.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNSCLC, GI, and prostate are core oncology lanes.\u003c\/li\u003e\n\u003cli\u003eExisting assays already match clinical demand.\u003c\/li\u003e\n\u003cli\u003eChina has broad biomarker-testing adoption.\u003c\/li\u003e\n\u003cli\u003eFocused sales can raise current product share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePharma research services with existing drug developers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s Pharma Research and Development Services gives it a second way to earn from its NGS platform without leaving oncology. Its work with 8 named drug developers—AstraZeneca, Bayer, Johnson \u0026amp; Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA—supports repeat business and keeps the brand visible in the same market.\u003c\/p\u003e\n\u003cp\u003eThis is market penetration, not new-market expansion: the company is deepening share inside its current pharma-oncology base. The recurring partner model helps stabilize demand and can lift service volume per existing customer.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e8 active pharma relationships\u003c\/li\u003e\n\u003cli\u003eRepeat use of one NGS platform\u003c\/li\u003e\n\u003cli\u003eMore share in the same oncology niche\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBurning Rock’s Growth Play: Deeper China Penetration, Not New Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited can grow by taking more share from existing hospital and pharma accounts in China, not by entering new markets. Its FY2025 base of 8 pharma partners and oncology assays in NSCLC, GI, and prostate supports repeat use, cross-sell, and higher wallet share.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma partners\u003c\/td\u003e\n\u003ctd\u003e8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore focus\u003c\/td\u003e\n\u003ctd\u003eChina oncology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePenetration lever\u003c\/td\u003e\n\u003ctd\u003eRepeat testing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing Burning Rock Biotech Limited’s growth strategy across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Ansoff Matrix view for Burning Rock Biotech Limited to clarify growth options and reduce strategy uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of primary sources to validate Burning Rock Biotech growth paths across products and markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader rollout across additional PRC hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s In-Hospital Business fits market development: it keeps the same oncology tests, but places them in more PRC hospitals. China’s hospital network has 36,000+ hospitals, so each new site widens access without changing assay design. The upside comes from broader clinical adoption, faster ordering, and deeper test penetration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion from core city coverage into wider China\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited, based in Guangzhou, can scale its existing oncology menu beyond current strongholds into China’s 31 provincial-level markets and wider hospital systems. This is a low-product-change move: the same tests can reach more patients through new provincial referral chains and tiered hospitals. It fits domestic demand growth without redesigning the core assay portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUse of central lab services to reach new referring institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited can use its Central Laboratory Business to win new referring doctors, hospitals, and medical institutions in China without changing its tissue or liquid biopsy assays. China had about 4.82 million new cancer cases in 2022, so the referral pool is large and still underpenetrated. The move is mainly network expansion: more accounts, same test menu, faster access to established diagnostics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExisting oncology assays for more clinical users\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited can grow this market by selling its existing assays to more clinical users, not by changing the tests. Its portfolio already spans 9 cancer areas, including lung, gastrointestinal, prostate, breast, thyroid, ovarian, pancreatic, bladder, and lymphoma, so the next step is wider use by oncologists, pathology teams, and hospital laboratories. This is classic market development: same product, larger user base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e9 tumor areas already covered\u003c\/li\u003e\n\u003cli\u003eTargets oncologists and pathology teams\u003c\/li\u003e\n\u003cli\u003eExpands into hospital laboratories\u003c\/li\u003e\n\u003cli\u003eSame assays, wider adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicensed tests introduced to the Chinese market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited expanded its China market by licensing Myriad myChoice and DetermaRx, turning existing external assays into local offerings. This uses its China regulatory and commercial base to reach more clinicians and hospitals without building new products from scratch. It is a market expansion move built on licensed access, not product invention.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLocalize proven tests\u003c\/li\u003e\n\u003cli\u003eReach more hospitals\u003c\/li\u003e\n\u003cli\u003eUse existing China access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBurning Rock’s Growth Hinges on Wider Hospital Adoption in China\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s market development is selling the same oncology assays to more PRC hospitals, doctors, and referral chains. With 36,000+ hospitals and 4.82 million new cancer cases in China, growth comes from broader adoption, not new test design.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals in China\u003c\/td\u003e\n\u003ctd\u003e36,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew cancer cases\u003c\/td\u003e\n\u003ctd\u003e4.82 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eBurning Rock Biotech Limited Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad myChoice commercialization in China\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited's China commercialization license for Myriad myChoice is a clear product development move: it adds a new licensed tumor test to the portfolio and deepens the biomarker and homologous recombination deficiency offering. China had about 4.8 million new cancer cases in 2022, so adding a PARP-focused assay can widen value for existing oncology customers. It also expands Burning Rock Biotech Limited's menu without building the test from scratch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDetermaRx launch for early-stage lung cancer risk stratification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s licensing deal with Oncocyte Corporation gives it China rights to DetermaRx, a gene-expression test for early-stage lung cancer risk stratification. It adds a new, decision-focused product to Burning Rock’s oncology diagnostics menu and fits its existing clinical testing model.\u003c\/p\u003e\n\u003cp\u003eIn Ansoff terms, this is product development, not a new market push, because the company is selling a more specialized test into its current cancer-diagnostics base. The move can deepen share in a high-value lung cancer segment where post-surgery recurrence risk management is a key clinical need.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eParpMatch assay expansion for HRD-related testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited is using product development by deepening OncoScreen ParpMatch and OncoCompass ParpMatch, which already target HRD-linked genes such as BRCA1\/2. HRD testing matters in ovarian, breast, prostate, and pancreatic cancers, where PARP inhibitor use keeps expanding. This adds assay depth for existing users, which fits product development, not new market entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRefined liquid biopsy and tissue assay portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited can use product development to sharpen its liquid biopsy and tissue NGS platforms, adding more biomarkers and cancer panels across the oncology menu. China had about 4.82 million new cancer cases in 2022, so broader test coverage can lift clinical use across tumor types.\u003c\/p\u003e\n\u003cp\u003eRefining assay sensitivity, turnaround time, and sample types would help the company fit changing hospital needs, especially for advanced and recurrent cancers. This keeps Burning Rock aligned with more precise, treatment-linked diagnostics in a market that keeps shifting toward earlier and richer molecular testing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroaden cancer-type coverage\u003c\/li\u003e\n\u003cli\u003eImprove liquid and tissue assay depth\u003c\/li\u003e\n\u003cli\u003eSupport more clinical use cases\u003c\/li\u003e\n\u003cli\u003eMatch China’s changing diagnostic demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-driven companion diagnostic creation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s partner-led companion diagnostic work uses its existing pharma links with AstraZeneca, Bayer, Johnson \u0026amp; Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA to build new biomarker assays tied to treatment choice. This fits its cancer-therapy selection role and turns 8 active partner channels into product-led growth. New tests can expand use of the same core platform without starting from zero.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e8 pharma partners support assay pipeline\u003c\/li\u003e\n\u003cli\u003eBiomarkers can link to therapy decisions\u003c\/li\u003e\n\u003cli\u003eExisting ties lower launch friction\u003c\/li\u003e\n\u003cli\u003eGrowth comes from new tests, not new markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBurning Rock Expands Oncology Menu to Capture More of China’s Cancer Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited is pursuing product development by adding licensed tests like Myriad myChoice and DetermaRx to its oncology menu. China had about 4.8 million new cancer cases in 2022, so broader biomarker coverage can lift use in its current hospital base. It is also deepening HRD and companion-diagnostic panels, which expands value without entering new markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina cancer cases\u003c\/td\u003e\n\u003ctd\u003e4.8 million, 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew tests\u003c\/td\u003e\n\u003ctd\u003emyChoice, DetermaRx\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategy\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma Research and Development Services as a separate business line\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s Pharma Research and Development Services line widens the business beyond cancer testing and lab services into paid external R and D work. It serves pharmaceutical and biotech partners, not just hospitals, so revenue is tied to drug-development demand as well as diagnostics. That is a clear diversification move in the Ansoff Matrix: new services for a new customer group.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial collaboration with multiple drug developers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited works with at least 8 drug developers, including AstraZeneca, Bayer, Johnson \u0026amp; Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA. These ties move it beyond patient testing and into drug development research, so the company serves both clinical and R\u0026amp;D needs. That widens its addressable market into adjacent pharma services and deepens recurring collaboration revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicense-in and commercialization of third-party oncology tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s in-licensing of Myriad myChoice and DetermaRx shows it can sell third-party oncology tests, not just homegrown assays. That widens the portfolio, adds outside commercial partners, and cuts reliance on one internal pipeline; in FY2025, this matters as a broader mix can smooth revenue swings. It is a clearer Diversification move in the Ansoff Matrix, with China expansion built on licensed products plus new recurring test relationships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eService revenue beyond hospital diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited serves hospitals and biopharma sponsors, so its service revenue spans two oncology demand pools. That mix matters: hospital testing follows clinical adoption, while pharma research services follow drug R\u0026amp;D budgets and trial timing. With China seeing about 4.8 million new cancer cases in 2022, diversified service demand helps reduce reliance on one buyer group.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTwo demand streams\u003c\/li\u003e\n\u003cli\u003eDifferent buying cycles\u003c\/li\u003e\n\u003cli\u003eLess segment dependence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNGS platform applied to diagnostics and research services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited uses its NGS platform across tissue testing, liquid biopsy, and pharma collaboration work, so the same core asset supports both patient-facing diagnostics and research services. That makes revenue less dependent on one line of business and gives the company more ways to monetize one scientific engine. One platform, multiple revenue streams.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eTissue, liquid biopsy, pharma services\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eSupports diagnostics and research\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eMore diversified than single-line peers\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBurning Rock’s FY2025 Diversification Spans Diagnostics, R\u0026amp;D, and Licensed Tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s Diversification is clear in FY2025: it sells pharma R\u0026amp;D services and licensed oncology tests alongside core diagnostics. That spreads revenue across hospitals and biopharma partners, with at least 8 drug developers and two demand cycles. One platform now supports testing and external research.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 diversification driver\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma R\u0026amp;D services\u003c\/td\u003e\n\u003ctd\u003e8+ drug developers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensed tests\u003c\/td\u003e\n\u003ctd\u003eMyriad products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234146820361,"sku":"bnr-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/bnr-ansoff-matrix.webp?v=1785713393","url":"https:\/\/dcfanalyst.com\/products\/bnr-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}